PM1080 / Jiangsu Hansoh Pharma, BioNTech - LARVOL DELTA

HS-20117 301: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=1080 | Recruiting | Sponsor: Hansoh BioMedical R&D Company | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=762 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=780 | Recruiting | Sponsor: Hansoh BioMedical R&D Company | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF

Phase Ib Trial of HS-20117 in Combination with Other Drugs in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=780 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF

HS-20117 301: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=1080 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

Metastases • New P2/3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates (PRNewswire) - "Biotheus Inc...and Hansoh Pharmaceutical Group Co., Ltd...jointly announced that the two parties will further expand their strategic collaboration, following their current partnership since 2022. Biotheus will grant Hansoh Pharma a license to use the proprietary anti-EGFR/cMet bispecific antibody PM1080/HS-20117 independently developed by Biotheus for the development of antibody-drug conjugates products (ADC Product). Under the terms of the agreement, Hansoh Pharma will obtain exclusive worldwide rights from Biotheus to use PM1080/HS-20117 for the development, production, and commercialization of ADC Product, with the right of sublicense."

Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=322 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Hansoh Pharmaceutical (03692.HK) Receives Notification of Clinical Trial for New Drug for Advanced Solid Tumors [Google translation] (Yahoo Finance) - "Hansoh Pharmaceuticals...announced that the Group's Class 1 new drug 'HS-20117' (PM1080), which was authorized by Pumisi, was approved by the China National Medical Products Administration and issued a clinical trial notification, which is intended to be used for the treatment of advanced solid tumors."

New trial • Oncology • Solid Tumor

Discovery and development of an asymmetric IgG-like bispecific antibody targeting EGFR and c-MET, engineered through H-H and H-L chain charge-based heterodimerization (AACR 2023) - "PM1080, a bispecific antibody targeting EGFR & c-MET was discovered for cancer treatment. PM1080 displayed potent anti-tumor efficacy either as a single agent or in combination with EGFR TKIs. Preclinical PK and toxicity studies have been conducted to support future first-in-human studies."

Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory (PRNewswire) - "Biotheus Inc...announced...that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus' EGFR/MET bispecific antibody (also known as PM1080) in Greater China, including Mainland China, Hong Kong, Macao and Taiwan....Under the terms of the agreement, Hansoh will be granted by Biotheus the exclusive rights to develop, commercialize and manufacture PM1080 for the treatment of cancer, and shall assume all the costs accordingly in the territory. In return, Biotheus will receive 50 million CNY and is entitled to receive up to ~1.4 billion CNY for future development, regulatory and commercialization milestones, plus tiered royalty payments based on net sales."

Licensing / partnership • Oncology